Clinical Application of PINK1 and ACSL4 Protein Levels in the Acute Myocardial Infarction Patients and Prognosis Evaluation After PCI

Abstract

Objective

To explore the clinical application of PTEN-induced kinase 1 (PINK1) and acyl-CoA synthetase long chain family 4 (ACSL4) protein levels in patients with acute myocardial infarction (AMI) and the prognosis evaluation after percutaneous coronary intervention (PCI).

Methods

152 AMI patients who underwent PCI at our hospital from October 2021 to February 2023 were selected as the study group. They were divided into a MACE group (31 cases) and a non MACE group (121 cases) based on the major adverse cardiovascular events (MACE) within 28 days after PCI. Additionally, 152 angina pectoris patients admitted during the same period were selected as the control group. Measure and analyze the levels and clinical significance of PINK1 and ACSL4 proteins in all study subjects.

Results

The PINK1 protein level in the study group was lower than that in the control group, while the PINK1 protein level in the MACE group was lower than that in the non MACE group (P<0.05), while the ACSL4 protein level was the opposite (P<0.05); PINK1 expression was negatively correlated with SYNTAX score (r=−0.602, P<0.05), while ACSL4 expression was positively correlated with SYNTAX score (r=0.683, P<0.05); Age, LVEF, and ACSL4 were risk factors for poor prognosis in AMI patients after PCI, while PINK1 was a protective factor (P<0.05); The combined prediction of PINK1 and ACSL4 for the postoperative prognosis of AMI patients after PCI was superior to the individual detection of PINK1 and ACSL4 (P<0.05).

Conclusion

The expression levels of PINK1 and ACSL4 are related to the occurrence of AMI, and their combined detection has high predictive power for the prognosis of AMI patients after PCI.

Keywords:

• acute myocardial infarction
• PTEN-induced kinase 1
• Acyl-CoA synthetase long chain family 4
• percutaneous coronary intervention
• prognosis

Data Sharing Statement

Data is available from the corresponding author on request.

Ethics Approval and Consent to Participate

The study involving human participants were reviewed and approved by the Ethics Committee of Yueyang People’s Hospital, Hunan Normal University (Ethical approval number:20220617) and with the 1964 Helsinki Declaration. Written informed consent to participate in this study was provided by all participants.

Disclosure

The authors declare no conflicts of interest in this work.

Additional information

Funding

No funding was provided for this research.